Reduce costly preclinical-to-IND mistakes before studies run
Independent protocol and PK/PD dosing plan risk review for biotech and translational teams. Get clarity and confidence before you execute.
Accelerate your roadmap
Aquarius gives biotech and translational teams an independent review so you can ship protocol and dosing decisions in record time—with fewer surprises at IND or in the clinic.
Without Aquarius
Lower quality protocol decisions, significant rework, and a long tail of edge cases discovered late.
Rework
Often significant
Risk detection
Often late
With Aquarius
Clearer dosing rationale, fewer protocol amendments, and earlier risk detection—independent review before you lock the plan.
Rework
Less
Risk detection
Earlier
Outcomes vary by project; we focus on clarity, fewer amendments, and earlier risk detection.
What we offer
Protocol & PK/PD risk review
Independent review of your protocol and dosing plan before studies run. Identify gaps, assumptions, and regulatory risks so you can fix them early—not at the agency or in the clinic.
Learn moreCRO-readiness & alignment
Ensure CRO-facing protocols, timelines, and data expectations are clear and aligned. Reduce rework and miscommunication.
Learn moreDDQ and accuracy focus
Due diligence support for investors and teams who need a concise memo on protocol and PK/PD risk—with a focus on accuracy you can ship on.
Learn moreTurn your protocol into high-confidence decisions
Book a CallTrusted by biotech and translational teams